Compare Abbott Laboratories (ABT) vs Global E Online Ltd (GLBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Global E Online Ltd — how do they compare? Abbott Laboratories trades at $95.83 (market cap $166.94B), while Global E Online Ltd trades at $35.83 (market cap $6.21B). The key difference: Abbott Laboratories is far larger — about 26.9× Global E Online Ltd's market cap, and Abbott Laboratories pays a 2.63% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.
| ABT | GLBE | |
|---|---|---|
Market Cap | $166.94B | $6.21B |
Sector | Health | Technology |
52-Week High | $136.62 | $41.59 |
52-Week Low | $82.57 | $27.54 |
Enterprise Value | $193.69B | $5.68B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
GLBE trades at $37.31, up 1.25% today, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with 33% revenue growth in Q1 2026 and expanding adjusted EBITDA margins to 19.9%. Recent acquisition of Passport enhances logistics capabilities, while a $500 million share repurchase program signals management confidence. Technical indicators show the stock trading near resistance at $38 with RSI levels suggesting potential overbought conditions.
GLBE presents a compelling growth story with accelerating international expansion and strong merchant adoption. However, elevated valuation multiples (P/E of 55.69) and recent insider selling warrant caution. The stock's proximity to analyst price targets suggests limited near-term upside, while execution risks around the Passport integration represent key challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →
